ARCHIVES

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

This article is from The Cancer Letter archive.

Vol. 31 No. 03 | January 21, 2005

Download PDF Visit The Full Archive

Related Articles

Study: Drug Discounts Used For Wealthier Patients In Many 340B-Enrolled Hospitals

October 10, 2014

NCCS Selects New President

October 9, 2009

PRI, Fending Off More Giants, Reportedly wins New operations. Support contract at Frederick

July 10, 1987

Interview With Screening Expert Barnett Kramer, PLCO Investigator

March 20, 2009

In Brief: Lombardi Comprehensive Designation Renewed; Yale Plans Breast Cancer Lab

September 26, 1997

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

November 28, 2014